Illumina’s Alliance for Genomic Discovery has now sequenced over 250,000 genomes from the Vanderbilt BioVU biobank and added pharmaceutical partners including Alnylam, expanding industry access to large, clinically linked genomic datasets. Illumina says the alliance will soon add another 30,000 samples and broaden data types to include proteomics. Pharma partners report using the data for target discovery, real‑world evidence and clinical development questions that require population scale.